Psilocybin compositions
Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
1 . A method for reducing symptoms of depression in a subject in need thereof comprising:
administering a dosage form comprising:
0.1 mg to 10 mg of psilocybin or psilocin;
an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; and
1 mg to 50 mg of niacin;
sufficient to reduce the symptoms of depression in the subject.
2 . The method of claim 1 , wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin.
3 . The method of claim 1 , wherein the dosage form further comprises one or more pharmaceutically acceptable excipients.
4 . The method of claim 1 , wherein the dosage form further comprises: extracts of Bacopa monnieri, Centella asiatica, Gingko biloba, Zingiber officinale, Ocimum sanctum, Polygonum cuspid atum, Origanum vulgare, Origanum onites, Rosmarinus officinalis, Rosmarinus eriocalyx, Curcuma longa, Camellia sinensis, Lavandula species, Scutellaria lateriflora, Avena sativa and Avena byzantine, Salvia divinorum, Banisteriopsis caapi, Psychotria species, Tabemanthe iboga, Voacanga africana, Tabemaemontana undulate, Ipomoea tricolor, Argyreia nervosa, Cannabis sativa, Cannabis indica, Cannabis ruderalis, or combinations thereof.
5 . The method of claim 1 , wherein the dosage form further comprises: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia , Beauveria , Copelandia , Cordyceps , Ganoderma , Grifola , Hericium , Inonotus , Isaria , Panaeolus , Phellinus , or combinations thereof.
6 . The method of claim 1 , wherein the dosage form is a capsule.
7 . The method of claim 1 , wherein 500 mg to 1000 mg of the composition is administered once to three times per day.
8 . A method for reducing symptoms of depression in a subject in need thereof comprising:
administering a dosage form comprising:
0.1 mg to 10 mg of psilocybin or psilocin; and
an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones;
sufficient to reduce the symptoms of depression in the subject.
9 . The method of claim 8 , wherein the dosage form further comprises 1 mg to 50 mg of niacin.
10 . The method of claim 8 , wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin.
11 . The method of claim 8 , wherein the dosage form further comprises one or more pharmaceutically acceptable excipients.
12 . The method of claim 8 , wherein the dosage form further comprises: extracts of Bacopa monnieri , Centella asiatica , Gingko biloba , Zingiber officinale , Ocimum sanctum , Polygonum cuspid atum , Origanum vulgare , Origanum onites , Rosmarinus officinalis , Rosmarinus eriocalyx , Curcuma longa , Camellia sinensis , Lavandula species , Scutellaria lateriflora , Avena sativa and Avena byzantine , Salvia divinorum , Banisteriopsis caapi , Psychotria species , Tabemanthe iboga , Voacanga africana , Tabemaemontana undulate , Ipomoea tricolor , Argyreia nervosa , Cannabis sativa , Cannabis indica , Cannabis ruderalis , or combinations thereof.
13 . The method of claim 8 , wherein the dosage form further comprises: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia , Beauveria , Copelandia , Cordyceps , Ganoderma , Grifola , Hericium , Inonotus , Isaria , Panaeolus , Phellinus , or combinations thereof.
14 . The method of claim 8 , wherein the dosage form is a capsule.
15 . The method of claim 8 , wherein 500 mg to 1000 mg of the dosage form is administered once to three times per day.
16 . A method for reducing symptoms of depression in a subject in need thereof comprising:
administering a dosage form comprising:
0.1 mg to 10 mg of psilocybin or psilocin;
1 mg to 50 mg of niacin;
sufficient to reduce the symptoms of depression in the subject.
17 . The method of claim 16 , wherein the dosage form further comprises an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones.
18 . The method of claim 16 , wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin.
19 . The method of claim 16 , wherein the dosage form further comprises one or more pharmaceutically acceptable excipients.
20 . The method of claim 16 , wherein the dosage form further comprises: extracts of Bacopa monnieri , Centella asiatica , Gingko biloba , Zingiber officinale , Ocimum sanctum , Polygonum cuspid atum , Origanum vulgare , Origanum onites , Rosmarinus officinalis , Rosmarinus eriocalyx , Curcuma longa , Camellia sinensis , Lavandula species, Scutellaria lateriflora , Avena sativa and Avena byzantine , Salvia divinorum , Banisteriopsis caapi , Psychotria species, Tabemanthe iboga , Voacanga africana , Tabemaemontana undulate , Ipomoea tricolor , Argyreia nervosa , Cannabis sativa , Cannabis indica , Cannabis ruderalis , or combinations thereof.
21 . The method of claim 16 , wherein the dosage form further comprises: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia , Beauveria , Copelandia , Cordyceps , Ganoderma , Grifola , Hericium , Inonotus , Isaria , Panaeolus , Phellinus , or combinations thereof.
22 . The method of claim 16 , wherein the dosage form is a capsule.
23 . The method of claim 16 , wherein 500 mg to 1000 mg of the dosage form is administered once to three times per day.